Flurbiprofen (Aryflam)

Listings for this ingredient that could not be applied to this product

• S4: Flurbiprofen

  • when intended for ophthalmic use; (S4)
  • except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S1)
  • except when intended for application to the skin, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
  • except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)

  Consolidated Schedules 06 July 2026, lines 6390 to 6407

• S3: Flurbiprofen

  • when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
  • when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i). a maximum of 8,75 milligrams per lozenge; (ii). a maximum treatment period of 3 days; and (iii). a maximum pack size of 15 lozenges. (S1)
  • except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
  • when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
  • when intended for ophthalmic use; (S4)

  Consolidated Schedules 06 July 2026, lines 3609 to 3620

• S2: Flurbiprofen

  • when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
  • except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii)a maximum pack size of 15 lozenges. (S1)
  • except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks; (S0)
  • except when intended for ophthalmic use. (S4)

  Consolidated Schedules 06 July 2026, lines 2014 to 2025

• S1: Flurbiprofen

  • when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S3)
  • except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks (S0)
  • except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
  • except when intended for ophthalmic use. (S4)

  Consolidated Schedules 06 July 2026, lines 465 to 482

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.